Optimer Pharmaceuticals, Inc. (OPTR) Posts Q2 EPS Loss of $0.52
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Financial Fact:
Research and development: 10.94M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Financial Fact:
Research and development: 10.94M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) reported Q2 EPS of ($0.52), $0.13 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $33.29 thousand versus the consensus estimate of $260 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Boston Beer Co. (SAM) Tops Q3 EPS by 15c; offers guidance
- SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
- Autoliv (ALV) Misses Q3 EPS by 7c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
